DAVID GRANOVSKY

Posts Tagged ‘adipose’

Belgian scientists repair bones with new stem cell technique – CBS News

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on January 16, 2014 at 12:49 pm

A piece of a three-dimensional bone structure obtained from the own adipose stem cells of a patient is seen at Brussels’ Saint Luc Hospital January 14, 2014. Belgian medical researchers have succeeded in repairing bones using stem cells from fatty tissue, with a new technique they believe could become a benchmark for treating a range of bone disorders. REUTERS

BRUSSELS  — Belgian medical researchers have succeeded in repairing bones using stem cells from fatty tissue, with a new technique they believe could become a benchmark for treating a range of bone disorders.

The team at the Saint Luc university clinic hospital in Brussels have treated 11 patients, eight of them children, with fractures or bone defects that their bodies could not repair, and a spin-off is seeking investors to commercialize the discovery.

Doctors have for years harvested stem cells from bone marrow at the top of the pelvis and injected them back into the body to repair bone.

The ground-breaking technique of Saint Luc’s centre for tissue and cellular therapy is to remove a sugar cube sized piece of fatty tissue from the patient, a less invasive process than pushing a needle into the pelvis and with a stem cell concentration they say is some 500 times higher.

The stem cells are then isolated and used to grow bone in the laboratory. Unlike some technologies, they are also not attached to a solid and separate ‘scaffold’.

“Normally you transplant only cells and you cross your fingers that it functions,” the centre’s coordinator Denis Dufrane told Reuters television.

His work has been published in Biomaterials journal and was presented at an annual meeting of the International Federation for Adipose Therapeutics and Science (IFATS) in New York in November.

 

2014-01-15T161731Z_858177456_GM1EA1F1UL301_RTRMADP_3_BELGIUM-MEDICINE.JPG
Belgian Professor Denis Defrane, coordinator of the centre of tissue and cellular therapy of Brussels’ Saint Luc Hospital, shows how a hole in the tibia of a patient suffering from a disease was treated on an x-ray, in Belgium January 14, 2014.
REUTERS

 

Bone Formation

“It is complete bone tissue that we recreate in the bottle and therefore when we do transplants in a bone defect or a bone hole…you have a higher chance of bone formation.”

The new material in a lab dish resembles more plasticine than bone, but can be molded to fill a fracture, rather like a dentist’s filling in a tooth, hardening in the body.

Some of those treated have included people recovering from tumors that had to be removed from bones. One 13-year-old boy, with a fracture and disorder that rendered him unable to repair bone, could resume sports within 14 months of treatment.

“Our hope is to propose this technology directly in emergency rooms to reconstitute bones when you have a trauma or something like that,” Dufrane said.

A spin-off founded last year called Novadip Biosciences will seek to commercialize the treatment, initially to allow spinal fusion among elderly people with degenerated discs.

It may also seek to create a bank of bone tissue from donors rather than the patients themselves.

IFATS president Marco Helder, based at Amsterdam’s VU university medical centre, said the novelty was the lack of solid scaffold.

“It is interesting and it is new, but it will have limitations regarding load-bearing capacity and, as with other implants, it will need to connect to the blood vessels of the body rapidly to avoid dying off,” he said, adding:

“Any foreign object can cause irritation and problems, so the fact that this is just host tissue would be an advantage.”

Belgian scientists repair bones with new stem cell technique – CBSNews.

 

RELATED STORY:

Critical size bone defect reconstruction by an autologous 3D osteogenic-like tissue derived from differentiated adipose MSCs.

http://www.ncbi.nlm.nih.gov/pubmed/23507085

STEM CELLS 101 – making sense of the mess

In ALL ARTICLES on September 23, 2011 at 4:21 am

STEM CELLS MAKING YOU CRAZY?!!!

https://i2.wp.com/www.thedogandthediva.com/wp-content/uploads/confused.bmp

Embryonic? Adult? induced Pluripotent? Omnipotent? Tutipotent? Umbilical? Fetal? Placental? Mesynchymal? Adipose?  Are you confused by it all?

CAN ANYONE MAKE SENSE OF THIS MESS OF INFORMATION!?!?!

STEM CELLS 101

ADULT STEM CELL = ASC

  • SOURCE/DERIVED FROM•comes from blood, umbilical cords, bone marrow, placenta fat tissue, muscle, nasal neurological, breast milk, menstruation, dental pulp, and many more
  • PURPOSE IN BODY•they are the body’s natural healing cells
  • OBSTACLES+SIDE EFFECTS•~zero problems (virtually zero side effects)
  • TREATMENT HISTORY•used in bone marrow transplants to treat cancer for 40 years
  • TREATMENT HISTORY•can currently treat 130+ diseases safely and effectively (CP, MS, Autism, Diabetes, CHF, PAD, etc)

EMBRYONIC STEM CELL = ESC

  • SOURCE/DERIVED FROM•comes from embryos
  • PURPOSE IN BODY•split for 7 weeks until you have a fetus the size of a thumbnail
  • OBSTACLES+SIDE EFFECTS•they create cysts and tumors, rejection requires immunosuppressive drugs for the ill patient, they carry the genetic anomalies of the donor, etc
  • TREATMENT HISTORY•can currently treat zero diseases, probably need to cure cancer first to use them

INDUCED PLURIPOTENT STEM CELL = iPSC (“Embryonic Stem Cell Lite”)

  • SOURCE/DERIVED FROM•comes from regular adult cells like skin cells that are then transformed by scientists into stem cells
  • PURPOSE IN BODY•to be a skin cell or other tissue
  • OBSTACLES+SIDE EFFECTS•they create cysts and tumors, rejection requires immunosuppressive drugs for the ill patient, they carry the genetic anomalies of the donor…
  • TREATMENT HISTORY•no treatments to date, probably need to cure cancer first to use them
FOR MORE INFORMATION ABOUT A SPECIFIC DISEASE OR STEM CELL TREATMENT COSTS AND INFORMATION OR TO LEARN WHERE PATIENTS CAN BE TREATED TODAY, PLEASE CONTACT ME: dsgrano@gmail.com

 

Worldwide Medical Conference Draws over 30 Countries, 150 Top Scientists to Indianapolis, Indiana

In STEM CELLS IN THE NEWS on July 19, 2010 at 2:39 pm

Worldwide Medical Conference Draws over 30 Countries, 150 Top Scientists to Indianapolis, Indiana

The International Federation of Adipose Therapeutics and Science (IFATS) is holding their 2007 world medical and research conference in Indianapolis, Indiana, October 18-20. The conference will present advancements in research of Adipose derived stem cells This will be the last IFATS conference to be held in the United States in the near future, as the conference moves to France next year and South Korea in 2009.

Multidisciplinary investigators from over 30 countries will attend the three-day conference, hosted by Keith L. March, MD, PhD, current IFATS president, Professor of Medicine, Physiology, and Biomedical Engineering, Indiana University School of Medicine.

This is the only organization that focuses on the understanding and treatment of disease by probing into the characteristics of adipose tissue and its rich repository of stem cells. This meeting will be more exciting than ever before, with the field of adipose stem cells having demonstrated a truly remarkable growth in interest over the last year. This is based on a progressive recognition of the host of possibilities for addressing diseases that affect very many people, including those with heart disease, problems with circulation to the legs, stroke, neurological disorders, diabetes, obesity, hemophilia, autoimmune diseases, kidney disease, bone and joint problems, and others.

More than 150 researchers from over 30 countries will join with representatives from more than 15 companies that are actively working in the area of adipose stem cells. Keynote lectures from scientists who have made truly seminal contributions in the translational science of other important types of adult stem cells will greatly enrich the 2007 conference. Dr. Anthony Atala (leader in the field of amniotic-fluid derived stem cells). Dr. Hal Broxmeyer (discover of umbilical cord-blood derived stem cells), and Dr. Katarina LeBlanc (leader in the field of bone-marrow derived mesenchymal stem cells) will lecture in their respective disciplines. Biosketches of each of these speakers is available on the IFATS website: http://www.ifats.org. A number of new clinical trials using or planning the use of adipose stem cells in patients will be discussed by the investigators.

via Worldwide Medical Conference Draws over 30 Countries, 150 Top Scientists to Indianapolis, Indiana.

Stem Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial

In VICTORIES & SUCCESS STORIES on May 7, 2010 at 4:31 pm

Cytori Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial

SAN DIEGO, May 07, 2010 (BUSINESS WIRE) — The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump…

via Cytori Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial – MarketWatch.

WORKING ON COPD CURES WITH STEM CELLS FROM FAT

In ALL ARTICLES on August 22, 2009 at 10:51 am

newspaper12

BIO-MATRIX SCIENTIFIC SUBSIDIARY FILES STEM CELL THERAPY APPLICATION FOR COPD

Issue 38, Volume 9, August 21, 2009, Joan Costello, Editor

Bio-Matrix Scientific Group, Inc. announced its majority owned subsidiary, Entest BioMedical unit has filed a patent application for the use of *adipose derived stem cells in the treatment of COPD. BMSN is excited with the progress achieved by Entest BioMedical, Inc. in identifying diseases it believes will be treatable through Stem Cell Therapy.

COPD is a major health disorder that appears to be treatable through adipose derived stem cell therapy. Currently, this disease is treated in similar fashion to asthma, utilizing inhalers and /or oxygen therapy. These methods are not solutions to the disease but merely provide the patient with greater level of comfort. Steven Josephs, PhD. noted, “The approach is intended at the very least to alleviate the chronic inflammation in COPD. This is done by using agents known to coax adult stem cells that are delivered to the diseased lung tissue (blood monocyte cells) to release cytokines (biologically active molecules) which in addition to the anti-inflammatory effects may actually promote the regeneration of functional lung tissue.”

The goal of Entest BioMedical, Inc. is to develop a stem cell therapy that reverses the effects of COPD on the respiratory system. The Company is working with Dr. Feng Lin, its Scientific Director and Steven Josephs, PhD in developing this stem cell treatment.

Cryo-Save India to launch human adipose tissue stem cells storage services – Biotechnology

In ALL ARTICLES on August 17, 2009 at 12:53 am
Fat is good!

Fat is good!

Monday, August 17, 2009 08:00 IST

Gireesh Babu, Mumbai

Cryo-Save India Pvt Ltd, the wholly-owned subsidiary of the Belgium-based adult stem cell storage bank major Cryo-Save Group, is exploring options to launch services to collect and store stem cells from human adipose tissues after liposuction as a potential aid to treating diseases.

The Indian launch will be in line with the parent company’s global launch of the new service by the end of 2009, according to V R Chandramouli, managing director, Cryo-Save India. The Cryo-Save, Europe’s largest adult stem cell storage bank, is developing a technique called Cryo-Lip to retrieve, process and store mesenchymal stem cells (MSC) from fatty tissue, which is now considered as a waste after liposuction.

via Cryo-Save India to launch human adipose tissue stem cells storage services – Biotechnology.

Fat-Derived Stem Cells Might Treat MS – US News and World Report

In ALL ARTICLES, CATCH UP! on April 26, 2009 at 5:08 pm

There are probably more than a dozen articles on here to speak of stem cells treating MS successfully over the past 4-6 years.  One day the US might catch up but it doesn’t look promising.

-dg

ms-multiple sclerosis

Fat-Derived Stem Cells Might Treat MS

Small study suggests they inhibit runaway immune system response

Posted April 26, 2009

SUNDAY, April 26 (HealthDay News) — Stem cells taken from the fat tissue of people with multiple sclerosis (MS) may help treat the disease, suggests a preliminary study that included three patients.

The successful use of the stromal vascular fraction (SVF) cells in these patients shows that further clinical studies should be conducted into the use of SVF cells to treat multiple sclerosis and other autoimmune diseases, the researchers said.

“All three patients in our study showed dramatic improvement in their condition after the course of SVF therapy. While obviously no conclusions in terms of therapeutic efficacy can be drawn from these reports, this first clinical use of fat stem cells for treatment of MS supports further investigation into this very simple and easily-implementable treatment methodology,” Dr. Boris Minev, division of neurosurgery at the University of California, San Diego, said in a news release.

In people with MS, the immune system attacks and destroys the myelin sheath that surrounds and protects nerves cells. It’s believed that SVF cells, and other stem cells, may limit this immune reaction and promote the growth of new myelin.

“None of the presently available MS treatments selectively inhibit the immune attack against the nervous system, nor do they stimulate regeneration of previously damaged tissue. We’ve shown that SVF cells may fill this therapeutic gap,” Minev said.

The study was published in the Journal of Translational Medicine.

via Fat-Derived Stem Cells Might Treat MS – US News and World Report.

People Who Read This Also Read

*

Hazardous Falls Don’t Have to Happen 23856996

*

Bill Maher’s Angry Rant Is Wrong About Republicans and Mainstream America 24097144

*

Miss California, Carrie Prejean: Finally, a Public Figure for Conservative Christians to Love 24051674

*

Stem Cell Breakthrough May Lead to MS Treatments 23791366

*

Rick Warren: Stopping Gay Marriage ‘Very Low’ on Priority List 23745272

Recommendations by Loomia

FAT STEM CELLS ARE GOOD FOR KIDNEY DAMAGE!

In ALL ARTICLES, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on March 1, 2009 at 11:43 am

kidney

kidney

Adipose (FAT)-Derived (ADULT) Stem And Regenerative Cells Prevent Mortality And Reduce Kidney Damage In Preclinical Study

Article Date: 01 Mar 2009 – 1:00 PST

Cytori Therapeutics, Inc. (NASDAQ: CYTX) finds adipose tissue-derived stem and regenerative cells (ADRCs) significantly reduce mortality and improve renal function in an acute kidney injury model. The preclinical results were reported today at the 14th Annual International Conference on Continuous Renal Replacement Therapies.

http://www.medicalnewstoday.com/articles/140616.php

CATCH UP! – FAT IS GOOD! (where stem cells are concerned)

In ALL ARTICLES, CATCH UP!, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on February 25, 2009 at 10:23 am
laughing_buddha_on_gold_ingot

laughing_buddha_on_gold_ingot

If you have the money and the interest, you can get your fat lipo’d out of your butt and injected into your face for a younger, smoother look.  And now, your fat can save your life!  A person’s own fat (adipose tissue) has been proved over many years to be a great source for stem cells.  Now Cytori has caught on.  Unfortunately, these are only pre-clinical trial trial results and the typical clinical trial lasts 7-10 years and costs $250-500 million, so…don’t hold your breath for treatments in the US anytime soon. – DG

Study Finds Adipose (Fat) Derived Stem, Regenerative Cells Significantly Reduce Mortality, Kidney Damage

February 25, 2009 9:23 AM EST

Cytori Therapeutics, Inc. (NASDAQ: CYTX) finds adipose tissue-derived stem and regenerative cells significantly reduce mortality and improve renal function in an acute kidney injury model. The preclinical results were reported today at the 14th Annual International Conference on Continuous Renal Replacement Therapies.

Acute kidney injury is a tremendous medical and financial burden to the healthcare system due to high mortality rates and the lack of effective therapies beyond supportive treatments. However, these new study findings by Cytori may lead to new therapeutic treatments using ADRCs that could reduce morbidity and mortality associated with acute kidney injury. Although this study was performed using a manual extraction technique, this potential application could be made more efficient and cost effective with the use of Cytori’s Celution(R) System to isolate clinical grade ADRCs in real time.

As part of the study design, acute kidney injury was induced in 29 preclinical research subjects by occluding blood flow into and out of both kidneys for 38 minutes. Twenty minutes after reperfusion of the kidneys, ADRCs or saline only were injected intra-arterially. All subjects were assessed daily for 7 days for markers of kidney function (serum creatinine and blood urea nitrogen) and survival.

After seven days, 100% of ADRC-treated preclinical subjects survived compared to only 57% in the control group (p<0.01). The ADRC-treated subjects also showed statistically significant improvements in kidney function, as measured by serum creatinine (p<0.0001) and blood urea nitrogen levels (p<0.0001). In addition, substantial improvement in the histologic structure within the kidney was observed, as measured by a reduction in tubular cell death and epithelial shedding (p<0.0001). This study suggests that ADRCs significantly accelerate renal repair and preserve renal function, offering a potential therapeutic approach in renal reparative medicine.

Kidney disease represents an annual cost of greater than $32 billion. More than 300,000 Americans are diagnosed with acute kidney injury annually, facing prolonged hospitalization, marked increases in morbidity as well as mortality.

via StreetInsider.com – Cytori Therapeutics’ (CYTX) Study Finds Adipose Derived Stem, Regenerative Cells Significantly Reduce Mortality, Kidney Damage.

%d bloggers like this: